Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Post-marketing surveillance of ZERBAXA for adult HABP/VABP in China
ChiCTR2600133833Phase 4Not yet recruiting
- Sponsor
- Zhejiang Provincial People's Hospital
- Start
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of ceftolozane in hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP), sponsored by Zhejiang Provincial People's Hospital. Primary endpoints: Adverse events, Adverse drug reactions and 4 more. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
ceftolozane
03
Conditions
hospital-acquired pneumonia (HAP)ventilator-associated pneumonia (VAP)
Beyond the preview
Go deeper on ChiCTR2600133833.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600133833.